Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation

<p>SNP ID.</p>

Zapisane w:

Opis bibliograficzny
1. autor:	Francesca Orzan (15055579) (author)
Kolejni autorzy:	Francesca De Bacco (15055582) (author), Elisabetta Lazzarini (15055585) (author), Giovanni Crisafulli (15055588) (author), Alessandra Gasparini (15019568) (author), Angelo Dipasquale (15055591) (author), Ludovic Barault (15030747) (author), Marco Macagno (15030744) (author), Pasquale Persico (15055594) (author), Federico Pessina (15055597) (author), Beatrice Bono (15055600) (author), Laura Giordano (15055603) (author), Pietro Zeppa (15055606) (author), Antonio Melcarne (15055609) (author), Paola Cassoni (15055612) (author), Diego Garbossa (15055615) (author), Armando Santoro (15034235) (author), Paolo M. Comoglio (15055618) (author), Stefano Indraccolo (15027102) (author), Matteo Simonelli (15055621) (author), Carla Boccaccio (15055624) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Therapeutic Research and Development Methods and Technology CNS Cancers Gliomas, Glioblastomas Liquid Biopsy Translational Research
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
od: Francesca Orzan (15055579)
Wydane: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
od: Francesca Orzan (15055579)
Wydane: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
od: Michael Kilian (16697663)
Wydane: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
od: Michael Kilian (16697663)
Wydane: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
od: Michael Kilian (16697663)
Wydane: (2025)

Supplementary Table S1 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
od: Mengjie Zhao (14845174)
Wydane: (2025)

Supplementary Table S2 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
od: Mengjie Zhao (14845174)
Wydane: (2025)

Supplementary Table S4 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
od: Mengjie Zhao (14845174)
Wydane: (2025)

Supplementary Table S5 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
od: Mengjie Zhao (14845174)
Wydane: (2025)

Supplementary Table S8 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
od: Mengjie Zhao (14845174)
Wydane: (2025)

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
od: Min Wu (14962986)
Wydane: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
od: Min Wu (14962986)
Wydane: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
od: Min Wu (14962986)
Wydane: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
od: Min Wu (14962986)
Wydane: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
od: William Kelly (15439117)
Wydane: (2025)

Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
od: William Kelly (15439117)
Wydane: (2025)

Data Sheet 3_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
od: Hailong Pang (12841991)
Wydane: (2025)

Data Sheet 2_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
od: Hailong Pang (12841991)
Wydane: (2025)

Data Sheet 1_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
od: Hailong Pang (12841991)
Wydane: (2025)

Table S1 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
od: N. Ari Wijetunga (15056183)
Wydane: (2025)

Table S2 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
od: N. Ari Wijetunga (15056183)
Wydane: (2025)

Table S3 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
od: N. Ari Wijetunga (15056183)
Wydane: (2025)

Table S4 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
od: N. Ari Wijetunga (15056183)
Wydane: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
od: Kala Visvanathan (14952973)
Wydane: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
od: Kala Visvanathan (14952973)
Wydane: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
od: Kala Visvanathan (14952973)
Wydane: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
od: Kala Visvanathan (14952973)
Wydane: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
od: Kala Visvanathan (14952973)
Wydane: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
od: Sied Kebir (15048732)
Wydane: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
od: Sied Kebir (15048732)
Wydane: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
od: Sied Kebir (15048732)
Wydane: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
od: Sied Kebir (15048732)
Wydane: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
od: Sied Kebir (15048732)
Wydane: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
od: Defne Bayik (14961098)
Wydane: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
od: Qingsheng Xu (17078830)
Wydane: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
od: Qingsheng Xu (17078830)
Wydane: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Wydane: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Wydane: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Wydane: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_r3io688badotsre1o0c3mmb973